Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 10 2022
11 10 2022
Historique:
received:
05
07
2022
accepted:
28
09
2022
entrez:
11
10
2022
pubmed:
12
10
2022
medline:
14
10
2022
Statut:
epublish
Résumé
This study aimed to investigate the clinical characteristics of patients with unresectable hepatocellular carcinoma (HCC), who were eligible for sequential systemic therapy. We evaluated 365 patients with HCC who underwent systemic therapy after 2017. The overall survival (OS) was 13.7 months, 19.2 months, and 35.6 months in the first-line, second-line, and third-line or later therapy groups, respectively. Multivariate analysis revealed that the modified-albumin-bilirubin (m-ALBI) grade, macrovascular invasion, extrahepatic spread, discontinuation due to adverse events (AEs), and sequential therapy were independent factors for OS. At the end of each therapy, the ALBI score was significantly worse among patients with discontinuation due to AEs than among those without. The conversion rate to second-line and third-line therapy among patients with discontinuation due to AEs was significantly lower than that among patients without (30.4% vs. 69.2%, p < 0.001; 6.7% vs. 58.3%; p < 0.001, respectively). In the decision tree analysis, m-ALBI grade 1 or 2a and non-advanced age were selected splitting variables, respectively, for sequential systemic therapy. In conclusion, sequential therapy prolonged the OS of unresectable HCC. Additionally, good hepatic function and non-advanced age were clinically eligible characteristics for sequential systemic therapy.
Identifiants
pubmed: 36220865
doi: 10.1038/s41598-022-21528-2
pii: 10.1038/s41598-022-21528-2
pmc: PMC9554046
doi:
Substances chimiques
Serum Albumin
0
Bilirubin
RFM9X3LJ49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17018Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Invest New Drugs. 2020 Feb;38(1):172-180
pubmed: 31172442
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Eur J Gastroenterol Hepatol. 2017 Jan;29(1):48-55
pubmed: 27623000
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Oncology. 2021;99(12):756-765
pubmed: 34518483
World J Hepatol. 2014 Sep 27;6(9):670-6
pubmed: 25276283
Target Oncol. 2021 May;16(3):411-412
pubmed: 33738697
Hepatol Res. 2011 Apr;41(4):296-302
pubmed: 21348907
Hepatol Res. 2022 May;52(5):462-470
pubmed: 35080087
Oncology. 2019;97(5):277-285
pubmed: 31307035
Hepatol Res. 2021 Dec;51(12):1219-1228
pubmed: 34534398
Liver Cancer. 2019 Oct;8(5):312-325
pubmed: 31768342
Onco Targets Ther. 2020 Nov 16;13:11725-11740
pubmed: 33235462
Hepatology. 2021 Jan;73 Suppl 1:158-191
pubmed: 32430997
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
J Hepatol. 2017 Jul;67(1):65-71
pubmed: 28192185
Clinics (Sao Paulo). 2021 Jan 22;76:e2498
pubmed: 33503195
PLoS One. 2020 Apr 10;15(4):e0231427
pubmed: 32275701
Liver Cancer. 2021 Dec 06;11(1):48-60
pubmed: 35222507
J Hepatol. 2022 Apr;76(4):874-882
pubmed: 34856322
Pharmaceuticals (Basel). 2021 Jan 06;14(1):
pubmed: 33418941
Cancer Med. 2014 Dec;3(6):1517-26
pubmed: 25045157
Hepatology. 2015 Sep;62(3):784-91
pubmed: 25645399
J Natl Cancer Inst. 2012 Apr 18;104(8):581-9
pubmed: 22457474
Cancer Med. 2021 Dec;10(23):8530-8541
pubmed: 34693661
Hepatol Int. 2017 Jul;11(4):317-370
pubmed: 28620797
Hepatol Res. 2021 Aug;51(8):880-889
pubmed: 33837620
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Cancer Med. 2019 Jul;8(8):3719-3728
pubmed: 31127698
Hepatol Res. 2016 Jun;46(7):650-6
pubmed: 26441378
Hepatol Res. 2020 Jan;50(1):75-83
pubmed: 31660700
Liver Cancer. 2021 Apr;10(2):107-114
pubmed: 33977087
Cancers (Basel). 2020 Jul 11;12(7):
pubmed: 32664489
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Oncology. 2020;98(11):787-797
pubmed: 32882687
Oncol Lett. 2020 Sep;20(3):2257-2265
pubmed: 32782543
Liver Cancer. 2021 Nov 23;11(1):75-84
pubmed: 35222509
Liver Int. 2021 Dec;41(12):2997-3008
pubmed: 34250737
Cancers (Basel). 2020 Apr 19;12(4):
pubmed: 32325921
Oncology. 2020;98(10):727-733
pubmed: 32712613
Hepatol Res. 2014 Aug;44(8):837-45
pubmed: 23819517
Dig Liver Dis. 2022 Apr;54(4):452-460
pubmed: 35131176
Cancers (Basel). 2019 Jul 07;11(7):
pubmed: 31284682